5 completed, 5 unknown, 3 recruiting, 2 not yet recruiting. 9 Phase 2, 7 Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Completed 2, Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 7 | Completed 3, Recruiting 2, Unknown 2 |
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Relapse Leukemia: new trials by email Literature Review of Relapse Leukemia trials Research Report on Relapse Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML VAH - Relapse Leukemia | Phase 2 | Not yet recruiting | Ruijin Hospital | 44 | 2025-08-01 | 2025-07-29 |
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
| Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML MTBF regimen - Relapse Leukemia, Refractory Acute Myeloid Leukemia | Not applicable | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 37 | 2024-05-01 | 2024-04-26 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia ALL, Childhood, Pediatric Cancer | Recruiting | University of Geneva, Switzerland | 556 | 2022-12-01 | 2026-01-15 | |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia chimeric antigen receptor T cell - Acute Myeloid Leukemia, Relapse Leukemia | Phase 1 / Phase 2 | Completed | Beijing Boren Hospital | 5 | 2021-04-08 | 2024-06-21 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-20 |
| Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy Venetoclax - Chronic Lymphocytic Leukemia, Relapse Leukemia | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 321 | 2020-07-24 | 2026-06-09 | |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML LP-108, LP-108 and azacitidine - AML/MDS, CMML | Phase 1 | Completed | Newave Pharmaceutical Inc | 32 | 2020-07-06 | 2026-01-23 |
| Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation blood sample, bone marrow sample - Relapse Leukemia, Allogeneic Stem Cell Transplantation | Not applicable | Unknown | Central Hospital, Nancy, France | 104 | 2019-09-01 | 2019-05-28 |
| Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Decitabine, mBU/CY and ATG, mBU/CY - Stem Cell Transplant Complications, Relapse Leukemia | Phase 2 / Phase 3 | Unknown | Peking University People's Hospital | 55 | 2018-12-01 | 2019-05-29 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
| Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia Cladribine, G-CSF, Aclarubicin - Acute Myeloid Leukemia, Relapse Leukemia | Phase 2 | Unknown | Sun Yat-sen University | 48 | 2016-01-01 | 2019-08-20 |
| Outcome Following Truncation of Asparaginase Relapse Leukemia | Completed | Birgitte Klug Albertsen | 1401 | 2008-07-01 | 2022-05-20 | |
| Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation the first donor's stem cell, the second donor's stem cell - Relapse Leukemia | Completed | huishengai | 20 | 2005-02-01 | 2016-07-13 |
Leukemia, Myeloid, Acute (7) · Leukemia (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Recurrence (2) · Anemia, Refractory, with Excess of Blasts (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Bone Marrow Failure Disorders (1) · Congenital Bone Marrow Failure Syndromes (1) · Drug-Related Side Effects and Adverse Reactions (1) · Genetic Predisposition to Disease (1) · Hematologic Neoplasms (1) · Hemoglobinopathies (1) · Hodgkin Disease (1)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Neoplasms by Histologic Type (13) · Neoplasms (12) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia (7) · Leukemia, Myeloid (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Leukemia, Lymphoid (6) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Lymphoma (3)
Aclarubicin (1) · Azacitidine (1) · Blood Specimen Collection (1) · Busulfan (1) · Cladribine (1) · Clinical Trials, Phase I as Topic (1) · Cytarabine (1) · Decitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Thiotepa (1) · aclacinomycins (1) · fludarabine (1) · revumenib (1) · venetoclax (1)
Beijing Boren Hospital (1) · Birgitte Klug Albertsen (1) · Central Hospital, Nancy, France (1) · Children's Hospital of Philadelphia (1) · Chongqing Precision Biotech Co., Ltd (1) · Ciusss de L'Est de l'Île de Montréal (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Memorial Sloan Kettering Cancer Center (1) · Newave Pharmaceutical Inc (1) · Peking University People's Hospital (1) · Ruijin Hospital (1) · Shenzhen University General Hospital (1) · Sun Yat-sen University (1) · University of Geneva, Switzerland (1)
China (7) · United States (3) · Canada (1) · Denmark (1) · India (1) · Italy (1) · Spain (1)
Denis-Claude Roy, MD PhD (1) · Jia Wei, M.D (1) · Jing Pan, MD/PhD (1) · Kuo-Kai Chin, MD (1) · Li Yu, Dr (1) · Liang Wang, M.D. (1) · Silvy Lachance, MD (1) · Timothy Olson, MD, PhD (1) · Xiao-Jun Huang (1) · Xiaoning Wang, M.D. (1) · Xiaoxia HU (1)